433 related articles for article (PubMed ID: 25131534)
21. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Finckh A; Simard JF; Gabay C; Guerne PA;
Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
[TBL] [Abstract][Full Text] [Related]
22. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
23. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study.
Pink AE; Fonia A; Allen MH; Smith CH; Barker JN
Br J Dermatol; 2010 Apr; 162(4):780-5. PubMed ID: 19863499
[TBL] [Abstract][Full Text] [Related]
24. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
[TBL] [Abstract][Full Text] [Related]
25. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
Cottone M; Kohn A; Daperno M; Armuzzi A; Guidi L; D'Inca R; Bossa F; Angelucci E; Biancone L; Gionchetti P; Ardizzone S; Papi C; Fries W; Danese S; Riegler G; Cappello M; Castiglione F; Annese V; Orlando A
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):30-5. PubMed ID: 20951835
[TBL] [Abstract][Full Text] [Related]
26. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
27. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
28. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
29. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
[TBL] [Abstract][Full Text] [Related]
30. The characteristics and clinical outcome of drug-induced liver injury: a single-center experience.
Idilman R; Bektas M; Cinar K; Toruner M; Cerit ET; Doganay B; Erden E; Bozkaya H; Bahar K; Karayalcin S; Soykan I; Palabiyikoglu M; Cetinkaya H; Yurdaydin C; Dokmeci A; Ozden A
J Clin Gastroenterol; 2010 Jul; 44(6):e128-32. PubMed ID: 20551776
[TBL] [Abstract][Full Text] [Related]
31. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
[TBL] [Abstract][Full Text] [Related]
32. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
Seror R; Richez C; Sordet C; Rist S; Gossec L; Direz G; Houvenagel E; Berthelot JM; Pagnoux C; Dernis E; Melac-Ducamp S; Bouvard B; Asquier C; Martin A; Puechal X; Mariette X;
Rheumatology (Oxford); 2013 May; 52(5):868-74. PubMed ID: 23287362
[TBL] [Abstract][Full Text] [Related]
33. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
Stephens C; Robles-Diaz M; Medina-Caliz I; Garcia-Cortes M; Ortega-Alonso A; Sanabria-Cabrera J; Gonzalez-Jimenez A; Alvarez-Alvarez I; Slim M; Jimenez-Perez M; Gonzalez-Grande R; Fernández MC; Casado M; Soriano G; Román E; Hallal H; Romero-Gomez M; Castiella A; Conde I; Prieto M; Moreno-Planas JM; Giraldez A; Moreno-Sanfiel JM; Kaplowitz N; Lucena MI; Andrade RJ;
J Hepatol; 2021 Jul; 75(1):86-97. PubMed ID: 33539847
[TBL] [Abstract][Full Text] [Related]
35. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.
Abreu C; Magro F; Santos-Antunes J; Pilão A; Rodrigues-Pinto E; Bernardes J; Bernardo A; Magina S; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
J Crohns Colitis; 2013 Nov; 7(10):e486-92. PubMed ID: 23583099
[TBL] [Abstract][Full Text] [Related]
36. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
[TBL] [Abstract][Full Text] [Related]
37. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.
Kotlyar DS; Osterman MT; Diamond RH; Porter D; Blonski WC; Wasik M; Sampat S; Mendizabal M; Lin MV; Lichtenstein GR
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):36-41.e1. PubMed ID: 20888436
[TBL] [Abstract][Full Text] [Related]
38. Anti-TNF-α and risk of infections: the experience in one center.
Maruotti N; D'Onofrio F; Neve A; Santoro N; Corrado A; Cantatore FP
Panminerva Med; 2014 Mar; 56(1):31-4. PubMed ID: 24637471
[TBL] [Abstract][Full Text] [Related]
39. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases.
Rodrigues S; Lopes S; Magro F; Cardoso H; Horta e Vale AM; Marques M; Mariz E; Bernardes M; Lopes J; Carneiro F; Macedo G
World J Gastroenterol; 2015 Jun; 21(24):7584-8. PubMed ID: 26140007
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.
Papa A; Felice C; Marzo M; Andrisani G; Armuzzi A; Covino M; Mocci G; Pugliese D; De Vitis I; Gasbarrini A; Rapaccini GL; Guidi L
J Crohns Colitis; 2013 Mar; 7(2):113-9. PubMed ID: 22464811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]